Delcath Systems (DCTH) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.07
- Estimate
- -$0.10
- Surprise
- +166.7%
- Revenue (period 2026-06-30)
- $29.1M
- Score at report (before → after)
- 7.1 → 7.0/10
Revenue source: xbrl.
How the report landed
Delcath Systems (DCTH) beat the -$0.10 estimate with diluted EPS of $0.07 — a large 166.7% upside surprise. TrendMatrix's engine moved from Hold (7.1/10) to Buy (Wait) at 7.0/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates DCTH Hold at 5.9/10.
3 of the last 4 quarters beat the estimate; this quarter's +166.7% surprise compares with a +78.5% four-quarter average. Next scheduled report: 2026-11-03.
What supports the rating
- Strong earnings beat streak (3/4)
- Wide economic moat
What argues against it
- Concentration risk — Product: HEPZATO
- Concentration risk — Supplier: melphalan supplier
- Near 52-week high (1.6% away)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $17.14
- Price target
- $20.88
- Stop
- $15.94
- Upside to target
- +21.8%
- Reward-to-risk
- 1.4:1
The stock trades at 1714.0× trailing but 380.9× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 74 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
DCTH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $594.7M
- P/E (fwd)
- 380.9
- P/E (ttm)
- 1714.0
- 52-week range
- $8.12–$17.42
- Off 52-week high
- 1.6%
- RSI (14)
- 74
- Volume vs avg
- 0.68×
- Score today
- 5.9/10